Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
AbbVie (ABBV) Q1 Earnings and Revenues Beat Estimates
09:55am, Friday, 25'th Apr 2025
AbbVie (ABBV) came out with quarterly earnings of $2.46 per share, beating the Zacks Consensus Estimate of $2.39 per share. This compares to earnings of $2.31 per share a year ago.
AbbVie lifts guidance as Q1 results top expectations
09:29am, Friday, 25'th Apr 2025
Abbvie Inc (NYSE:ABBV) shares moved higher after it reported strong results for the first quarter of 2025 and raised its full-year profit guidance. The company now expects adjusted earnings per share
If You Wanted To Buy AbbVie and Didn't, There's Still Time To Buy
09:25am, Friday, 25'th Apr 2025
If you have been or are thinking about getting into AbbVie NYSE: ABBV, there is still time to do so. The AbbVie stock price is in a sustained uptrend and will set new all-time highs repeatedly over ti
AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet.
08:03am, Friday, 25'th Apr 2025
First-quarter adjusted earnings per share were $2.46 on sales of $13.3 billion, above analysts' expectations.
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact Levi & Korsinsky
08:00am, Friday, 25'th Apr 2025
NEW YORK, NY / ACCESS Newswire / April 25, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the feder
AbbVie lifts profit forecast on strong sales of newer immunology drugs
07:47am, Friday, 25'th Apr 2025
AbbVie raised its 2025 profit forecast on Friday after strong sales of its newer immunology drugs Skyrizi and Rinvoq helped the company beat Wall Street estimates for first-quarter earnings.
AbbVie Reports First-Quarter 2025 Financial Results
07:43am, Friday, 25'th Apr 2025
Reports First-Quarter Diluted EPS of $0.72 on a GAAP Basis, a Decrease of 6.5 Percent; Adjusted Diluted EPS of $2.46, an Increase of 6.5 Percent; These Results Include an Unfavorable Impact of $0.13 P
5 Rock-Solid Passive Income Dividend Aristocrats That Are Reasonably Safe From Tariffs
06:41am, Friday, 25'th Apr 2025
The driving force behind the recent volatility in the stock and bond markets can be boiled down to one specific item: the threat of tariffs and a global trade war.
NEW YORK , April 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a cl
Lost Money on Cerevel Therapeutics Holdings, Inc.(ABBV)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
12:29pm, Thursday, 24'th Apr 2025
NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a
NEW YORK, NY / ACCESS Newswire / April 24, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the feder
AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines
08:30am, Thursday, 24'th Apr 2025
–TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and shorter duration of ef
NEW YORK , April 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV
Buy Stock in These Healthcare Leaders as Q1 Earnings Approach? ABBV, HCA
08:10pm, Wednesday, 23'rd Apr 2025
The medical sector can provide a defensive hedge against economic uncertainty, and investors may be eyeing AbbVie (ABBV) and HCA Healthcare (HCA) stock ahead of their Q1 reports on Friday, April 25.
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
